Federated Bayesian Optimization

The core privacy mechanism of FBO. Instead of transmitting raw validation metrics from each hospital, clients share only the parameters of a Gaussian Process (GP) or alternative probabilistic surrogate model. This surrogate encodes the relationship between hyperparameters and performance without revealing the underlying patient data distribution or model accuracy on specific cohorts. The central server aggregates these surrogate posteriors to construct a global acquisition function, guiding the next hyperparameter candidate selection without ever seeing individual client performance.

FBO operates in a sequential experimental design loop adapted for federated constraints:

• The server proposes a batch of hyperparameter configurations based on the aggregated surrogate
• Each client evaluates the configurations on its local validation set
• Clients return only surrogate model updates, not the evaluation scores
• The global model refines its belief about the objective landscape This iterative process efficiently finds optimal hyperparameters while maintaining a strict data minimization principle, crucial for HIPAA and GDPR compliance in multi-institutional clinical studies.

Clinical data across institutions is inherently non-IID—patient demographics, imaging protocols, and labeling standards vary significantly. FBO addresses this by allowing clients to maintain local surrogate models that capture site-specific performance landscapes. The aggregation step can employ weighted averaging based on dataset size or use more sophisticated techniques like Thompson sampling across client posteriors. This prevents the optimization from being dominated by a single large institution while still leveraging collective knowledge to accelerate convergence toward a globally robust configuration.

FBO dramatically reduces communication overhead compared to naive federated tuning approaches:

• Surrogate parameters are typically orders of magnitude smaller than full model weights or gradient vectors
• A Gaussian Process with a Matérn kernel may require transmitting only a few hundred floating-point values per round
• Batch evaluation allows multiple hyperparameter candidates to be assessed per communication round, further amortizing latency This efficiency makes FBO practical for cross-continental clinical research networks where bandwidth is limited and round-trip times are high.

FBO naturally extends to multi-fidelity optimization, where hyperparameter configurations are first evaluated on low-cost proxies before committing to full training. In federated settings, this means:

• Testing configurations on subsampled datasets or reduced training epochs locally
• Building surrogates that model performance across fidelity levels
• Pruning unpromising candidates early using Successive Halving or HyperBand adaptations This is critical in healthcare, where full model training on large imaging datasets may take hours per configuration, and wasted computation directly translates to delayed clinical deployment.

Advanced FBO implementations incorporate formal differential privacy (DP) protections into the surrogate sharing process. By adding calibrated noise to the transmitted surrogate parameters—typically via the Gaussian mechanism applied to kernel hyperparameters or inducing point values—clients can achieve (ε, δ)-DP guarantees. This provides a mathematically rigorous bound on the information leakage about any single patient's data, satisfying the strictest regulatory requirements for cross-institutional clinical research while still enabling effective collaborative hyperparameter optimization.

Pharmaceutical consortia use federated Bayesian optimization to tune inclusion/exclusion criteria for decentralized clinical trials without pooling sensitive patient records. Each hospital runs local trials, sharing only the Gaussian Process surrogate parameters that model the dose-response surface. This accelerates Phase II dose-finding while preventing any single institution from accessing another's proprietary trial data. The approach reduces trial costs by an estimated 30% compared to traditional centralized meta-analysis.

A network of hospitals collaboratively optimizes a chest X-ray classification model without sharing images. Each site computes local validation performance for candidate hyperparameter configurations proposed by the central acquisition function. Only the parameters of the surrogate model—not the validation metrics themselves—are transmitted. This prevents model inversion attacks that could reconstruct patient scans from shared performance data, maintaining HIPAA compliance while achieving diagnostic accuracy within 2% of centralized tuning.

Intensive care units deploy federated Bayesian optimization to calibrate vasopressor dosage models for septic shock patients. Each ICU's local model proposes dosage adjustments, and the Thompson sampling acquisition function balances exploration of new dosing strategies against exploitation of known effective ranges. The surrogate model aggregates knowledge across hospitals while keeping individual patient vitals and outcomes strictly local. This reduces mean time to hemodynamic stability by 18% compared to fixed protocols.

Multiple biobanks use federated Bayesian optimization to search for polygenic risk score configurations that predict disease susceptibility. Each biobank evaluates candidate SNP weightings locally, sharing only the expected improvement surface encoded in the surrogate model. This enables exploration of combinatorial genetic markers across millions of variants without exposing individual-level genotype data. The approach has identified novel Alzheimer's risk loci that were undetectable in single-biobank analyses.

Manufacturers of continuous glucose monitors apply federated Bayesian optimization to calibrate sensor algorithms across diverse patient populations. Each device runs local calibration experiments, and the Pareto frontier of accuracy versus power consumption is modeled via a shared Gaussian Process. The surrogate model identifies optimal calibration parameters without centralizing raw sensor readings or patient glucose logs. This yields a 22% improvement in mean absolute relative difference across heterogeneous skin types and activity levels.

Hospital networks perform federated neural architecture search to discover optimal transformer architectures for clinical note de-identification. Each site trains candidate architectures locally, and the Bayesian optimization loop shares only the learned embeddings of architecture-performance relationships. This prevents leakage of patient names or diagnoses through architecture performance signals. The resulting architecture achieves 99.7% PHI recall while using 40% fewer parameters than manually designed alternatives.